INNATE PHARMA SP.ADR/1 (IDDA) — Defensive Interval Ratio
INNATE PHARMA SP.ADR/1 (IDDA) has a Defensive Interval Ratio of 66 days as of December 2025. Defensive assets of €6.61 Million (cash €-, short-term investments €6.22 Million, receivables €391.00K) cover 66 days of daily cash needs of €100.41K/day.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
INNATE PHARMA SP.ADR/1 Defensive Interval Ratio (2021–2025)
This chart shows how INNATE PHARMA SP.ADR/1's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 66 days, meaning defensive assets of €6.61 Million can fund 66 days of operations without new revenue. For the complete balance sheet picture, see INNATE PHARMA SP.ADR/1 (IDDA) total assets.
Annual Defensive Interval Ratio for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below presents the year-by-year Defensive Interval Ratio for INNATE PHARMA SP.ADR/1 from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. See INNATE PHARMA SP.ADR/1 current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 66 days | €6.61 Million | €100.41K/day | €- | €6.22 Million | ▼ -100 days |
| 2024 | 166 days | €15.02 Million | €90.36K/day | €- | €14.37 Million | ▼ -175 days |
| 2023 | 341 days | €37.08 Million | €108.59K/day | €- | €21.85 Million | ▲ +162 days |
| 2022 | 180 days | €20.34 Million | €113.25K/day | €- | €17.26 Million | ▲ +102 days |
| 2021 | 77 days | €16.93 Million | €218.87K/day | €- | €16.08 Million | — |